基于TCGA和GEO数据库——联合挖掘肾透明细胞癌诊断和预后的生物标志物
摘要
关键词
全文:
PDF参考
[1]Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of Renal Cell Carcinoma. World J Oncol. 2020;11(3):79-87. doi:10.14740/wjon1279
[2]Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30(5):706-720. doi:10.1093/annonc/mdz056
[3]Wang G, Chen B, Su Y, et al. CEP55 as a Promising Immune Intervention Marker to Regulate Tumor Progression: A Pan-Cancer Analysis with Experimental Verification[J]. Cells, 2023, 12(20): 2457.
[4]Chen H, Zhu D, Zheng Z, Cai Y, Chen Z, Xie W. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway. Clin Transl Oncol. 2019;21(7):939-949. doi:10.1007/s12094-018-02012-8
[5]Capecchi MR, Pozner A. ASPM regulates symmetric stem cell division by tuning Cyclin E ubiquitination. Nat Commun. 2015;6:8763. Published 2015 Nov 19. doi:10.1038/ncomms9763
[6]吴莹莹,金木兰.ASPM在肿瘤中的作用机制及最新研究进展[J].诊断病理学杂志,2021,28(02):128-130.
[7]宋章兴,崔应东,李时军,等.肾透明细胞癌病理分级相关基因的WGCNA筛选[J].现代泌尿生殖肿瘤杂志,2021,13(01):9-15.
[8]魏灿,张艳斌,杨晓亮,等.垂体肿瘤转化基因1在肾透明细胞癌中的表达及其与预后的关系[J].中华实验外科杂志,2018,35(9):1610-1612.
[9]Iyer J, Moghe S, Furukawa M, Tsai MY. What's Nu(SAP) in mitosis and cancer?. Cell Signal. 2011;23(6):991-998. doi:10.1016/j.cellsig.2010.11.006
[10]苏天宇,张有为,王翔.KIF20A在肿瘤中的作用及调控机制研究[J].徐州医科大学学报,2024,44(05):368-374.
[11]Li J, Dallmayer M, Kirchner T, Musa J, Grünewald TGP. PRC1: Linking Cytokinesis, Chromosomal Instability, and Cancer Evolution. Trends Cancer. 2018;4(1):59-73. doi:10.1016/j.trecan.2017.11.002
[12]Li S, Motiño O, Lambertucci F, Martins I, Sun L, Kroemer G. Protein regulator of cytokinesis 1: a potential oncogenic driver. Mol Cancer. 2023;22(1):128. Published 2023 Aug 10. doi:10.1186/s12943-023-01802-1
[13]万梓宇,王霞,郑张节,等.PRC1靶向调控Hippo通路促进肾癌细胞增殖和迁移能力[J].武汉大学学报(医学版),2025,46(01):36-40.DOI:10.14188/j.1671-8852.2024.0087.
(3 摘要 Views, 1 PDF Downloads)
Refbacks
- 当前没有refback。